• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update

    Simply Wall St·08/22/2026 07:20:55
    Listen to the news
    • In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for AVT34 and AVT87 in the US and eight Asian markets, alongside guidance for full-year 2026 revenues of US$650–US$700 million and disclosure of a half-year 2026 net loss of US$65.79 million.
    • The Lotus deal, with potential value of about US$150 million in upfront and milestone payments plus ongoing supply revenues, gives Alvotech dual US commercialization channels while extending its reach into key Asian markets through Lotus and Alvogen.
    • Next, we’ll examine how the Lotus licensing deal and its US$150 million potential reshape Alvotech’s existing biosimilar investment narrative.

    We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Alvotech Investment Narrative Recap

    To own Alvotech, you need to believe its focused biosimilar model and partner network can turn a volatile, milestone‑heavy revenue mix into sustainable profitability. The Lotus deal adds another commercialization channel in the US and a new Asian footprint, but the most important near term catalyst still sits with timely regulatory approvals and inspections, while the biggest risk remains lumpy milestone revenues tied to those regulatory timelines. This latest agreement does not substantially change that risk balance in the short term.

    The updated 2026 revenue guidance of US$650–US$700 million is the clearest company signal tied to this period, and it sits alongside a half year 2026 net loss of US$65.79 million after a planned manufacturing slowdown. For me, that pairing matters more for the near term narrative than the headline US$150 million Lotus potential, because it frames how much room Alvotech has to absorb regulatory or partner related timing setbacks while still pushing its pipeline toward key milestones.

    Yet beneath the appeal of new partners and guidance, investors should be aware that the company’s dependence on lumpy milestone and licensing revenues could...

    Read the full narrative on Alvotech (it's free!)

    Alvotech's narrative projects $1.0 billion revenue and $242.3 million earnings by 2029. This requires 22.2% yearly revenue growth and a $323.0 million earnings increase from -$80.7 million today.

    Uncover how Alvotech's forecasts yield a $5.75 fair value, a 30% upside to its current price.

    Exploring Other Perspectives

    ALVO 1-Year Stock Price Chart
    ALVO 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already cautious, assuming about US$982.5 million revenue and US$82.7 million earnings by 2029, which reflects a far more restrained view of Alvotech’s ability to turn regulatory milestones into durable earnings than the more optimistic consensus, and the Lotus agreement may well prompt both groups to revisit those expectations.

    Explore 5 other fair value estimates on Alvotech - why the stock might be worth 10% less than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.